We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

7 hedge funds and large institutions have $13.8M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 229 closing their positions.

New
Increased
Maintained
Reduced
Closed

97% less funds holding in top 10

Funds holding in top 10: 32 → 1 (-31)

97% less funds holding

Funds holding: 240 → 7 (-233)

99% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 229

100% less capital invested

Capital invested by funds: $8.78B → $13.8M (-$8.77B)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
7
Holders Change
-233
Holders Change %
-97.08%
% of All Funds
0.11%
Holding in Top 10
1
Holding in Top 10 Change
-31
Holding in Top 10 Change %
-96.88%
% of All Funds
0.02%
New
2
Increased
–
Reduced
4
Closed
229
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BTI
Blue Trust Inc
Georgia
+$9.87K
2
MSCM
McElhenny Sheffield Capital Management
Texas
+$4.71K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$748M
2
UOC
UBS O'Connor
Illinois
-$572M
3
HI
HBK Investments
Texas
-$537M
4
Stifel Financial
Stifel Financial
Missouri
-$464M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$349M
Name Holding Trade Value Shares
Change 		Change in
Stake
LIP
1
Liontrust Investment Partners
United Kingdom
$7.48M – – –
KCM
2
Knoll Capital Management
Florida
$6.25M -$68.4M -450,422 -50%
BC
3
Birchview Capital
Vermont
$102K -$1.12M -7,365 -50%
BTI
4
Blue Trust Inc
Georgia
$10K +$9.87K +65 New
FIA
5
FNY Investment Advisers
New York
$3K -$40M -263,322 -100%
IA
6
IFP Advisors
Florida
$1K -$607 -4 -80%
MSCM
7
McElhenny Sheffield Capital Management
Texas
$430 +$4.71K +31 New
BlackRock
8
BlackRock
New York
– -$748M -4,949,917 Closed
UOC
9
UBS O'Connor
Illinois
– -$572M -3,784,482 Closed
HI
10
HBK Investments
Texas
– -$537M -3,550,000 Closed
Stifel Financial
11
Stifel Financial
Missouri
– -$464M -3,071,644 Closed
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
– -$349M -2,308,014 Closed
SFM
13
Soros Fund Management
New York
– -$344M -2,272,535 Closed
JP Morgan Chase
14
JP Morgan Chase
New York
– -$309M -2,041,718 Closed
FCM
15
Farallon Capital Management
California
– -$294M -1,947,820 Closed
State Street
16
State Street
Massachusetts
– -$267M -1,763,828 Closed
Capital International Investors
17
Capital International Investors
California
– -$231M -1,525,202 Closed
Vanguard Group
18
Vanguard Group
Pennsylvania
– -$218M -1,439,571 Closed
GCL
19
Glazer Capital LLC
New York
– -$187M -1,238,525 Closed
PCM
20
Pentwater Capital Management
Florida
– -$176M -1,163,000 Closed
RM
21
RP Management
New York
– -$168M -1,111,111 Closed
Janus Henderson Group
22
Janus Henderson Group
United Kingdom
– -$166M -1,099,328 Closed
Geode Capital Management
23
Geode Capital Management
Massachusetts
– -$166M -1,097,362 Closed
Goldman Sachs
24
Goldman Sachs
New York
– -$161M -1,062,350 Closed
TAL
25
TIG Advisors LLC
New York
– -$151M -1,001,653 Closed
1
2 3 4 5

BHVN Hedge Fund Activity: Q4 2022 in Review

7 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2022, worth a combined $13.8M — down 100% from $8.78B a quarter earlier.

Sellers outnumbered buyers: 229 funds closed out of BHVN and 2 opened new positions — a net loss of 227 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was Blue Trust Inc, opening a new position worth an estimated $9.87K. The largest seller was BlackRock, exiting entirely with an estimated $748M sold.

  • 7 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2022, down from 240 in Q3 2022.
  • Funds reported $13.8M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2022, down 100% quarter-over-quarter.
  • 2 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2022 and 229 closed out, a net change of -227 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2022 was Blue Trust Inc, an estimated $9.87K added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2022 was BlackRock, an estimated $748M sold.

Based on aggregated 13F filings for Q4 2022.